Pfizer has expanded its gene therapy portfolio in a deal valued at US$545 M with Sangamo Therapeutics. The collaboration includes the preclinical candidate, SB-525, which is in development for the treatment of haemophilia A. The agreement follows Pfizer’s August 2016 acquisition of gene therapy developer, Bamboo Therapeutics, and a licensing agreement with Spark Therapeutics for a haemophilia B gene therapy programme which was signed in 2014